StockpollyBeta
Get App
Delisting riskPopularity #4,473
XBIO · NASDAQ · Biotechnology

Xenetic Biosciences (XBIO)

Develops DNase-based adjuncts for cancer therapy and armored CAR-T treatment.

$2.57
After hours0.00 (0.00%)
At close$2.57(−14.05%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue111111111111
Gross profit111111111111
222212212112
Research & development111101111111
111111111111
General & administrative111111111111
Other expenses000000000000
Operating income−1−1−1−10−1−1−1−1−1−1−1
000000000000
Interest income000000000000
Other non-operating income000000000000
Income before tax−1−1−1−10−1−1−1−1−10−1
Net income from continuing operations−1−1−1−10−1−1−1−1−10−1
Net income−1−1−1−10−1−1−1−1−10−1
EPS, basic−$0.69−$0.76−$0.78−$0.83−$0.28−$0.68−$0.59−$0.45−$0.33−$0.25−$0.20−$0.41
EPS, diluted−$0.69−$0.76−$0.78−$0.83−$0.28−$0.68−$0.59−$0.45−$0.33−$0.25−$0.20−$0.41
Weighted average shares, basic222222222222
Weighted average shares, diluted222222222222
EBITDA−1−1−1−10−1−1−1−1−10−1
Depreciation & amortization000000000000
EBIT−1−1−1−10−1−1−1−1−10−1